NeoGenomics, Inc. (NASDAQ:NEO) Stock Position Increased by Oberweis Asset Management Inc.

Oberweis Asset Management Inc. boosted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 7.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 768,700 shares of the medical research company's stock after buying an additional 50,000 shares during the quarter. Oberweis Asset Management Inc. owned 0.60% of NeoGenomics worth $12,668,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Nordea Investment Management AB raised its holdings in shares of NeoGenomics by 2.8% in the 4th quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company's stock worth $1,301,000 after purchasing an additional 2,125 shares in the last quarter. Swiss National Bank boosted its stake in shares of NeoGenomics by 1.0% during the 4th quarter. Swiss National Bank now owns 252,100 shares of the medical research company's stock worth $4,155,000 after acquiring an additional 2,600 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of NeoGenomics by 18.7% in the 4th quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock worth $24,963,000 after acquiring an additional 238,288 shares during the last quarter. Rhumbline Advisers raised its position in shares of NeoGenomics by 2.4% during the fourth quarter. Rhumbline Advisers now owns 389,003 shares of the medical research company's stock worth $6,411,000 after purchasing an additional 9,098 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of NeoGenomics by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,161,352 shares of the medical research company's stock valued at $19,139,000 after purchasing an additional 26,701 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

NEO has been the topic of several recent analyst reports. Benchmark downgraded shares of NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. Piper Sandler decreased their price target on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. The Goldman Sachs Group decreased their target price on shares of NeoGenomics from $17.00 to $15.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Needham & Company LLC reduced their price objective on NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, February 19th. Finally, Bank of America cut their price target on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $19.30.

NeoGenomics Stock Up 1.6 %

NEO stock opened at $9.91 on Thursday. The business's 50-day simple moving average is $9.93 and its 200 day simple moving average is $13.52. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The company has a market cap of $1.27 billion, a PE ratio of -15.98 and a beta of 1.41. NeoGenomics, Inc. has a twelve month low of $8.05 and a twelve month high of $19.12.

NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The firm had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. On average, research analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.